Patent application EP19305448A (EP), filed 2019-04-05
Publication number: EP3714943A1
Title: MONOCLONAL ANTIBODY AGAINST STIM1
Abstract: [0001]    The present invention relates to a compound that specifically binds to the region between amino acid residues 58 and 201 of the human STIM1 amino acid sequence SEQ ID NO: 1.
[0002]    The present invention also relates to a composition comprising a therapeutically effective amount of the compound, a host cell that produces an isolated antibody, an isolated nucleic acid sequence encoding the isolated antibody and an expression vector comprising the nucleic acid.
[0003]    The present invention additionally relates to a method of producing the isolated antibody, to the isolated antibody for its use as a drug, especially for its use in treating a condition or a disorder in which the STIM1 protein localized to the plasma membrane of the cells is overexpressed, and to an isolated protein fragment consisting of the region between amino acid residues 58 and 201 for developing modulators of the STIM1 amino acid sequence SEQ ID NO: 1.
IPC codes: A61P  35/    00            A I
A61P  37/    00            A I
C07K  16/    28            A I
Claims: number: 1
text: A compound that specifically binds to the region between amino acid residues 58 and 201 of the STIM1 amino acid sequence SEQ ID NO: 1 and modulates STIM1 activity.
number: 2
text: A compound according to claim 1, that specifically binds to the region between amino acid residues 128 and 168 of the STIM1 amino acid sequence SEQ ID NO: 1 and modulates STIM1 activity.
number: 3
text: A compound according to claim 1, said compound being an activator or an inhibitor of STIM1 activity.
number: 4
text: A compound according to claim 1, said compound being chosen from the group comprising isolated antibodies or fragments thereof, proteins, peptides, chemical or natural compounds, aptamers or any biological compound.
number: 5
text: A compound according to claim 4, said compound being a peptide, the sequence of which corresponding to amino acid residues 58 to 201 of the STIM1 amino acid sequence SEQ ID NO: 1.
number: 6
text: A compound according to claim 4, said compound being an isolated antibody.
number: 7
text: An isolated antibody according to claim 6, comprising at least one sequence of the group consisting of:
number: 8
text: An isolated antibody according to claim 6 or 7, comprising at least one sequence of the group consisting of:
number: 9
text: An isolated antibody according to anyone of claims 6 to 8, comprising:
number: 10
text: An isolated antibody according to anyone of claims 6 to 9, comprising :
number: 11
text: An isolated antibody according to anyone of claims 6 to 10, which is a monoclonal antibody.
number: 12
text: An isolated antibody according to anyone of claims 6 to 11, which is a chimeric, human or humanized antibody.
number: 13
text: An isolated antibody according to anyone of claims 6 to 12, which is modified to be coupled with a drug, for example for enhancing ADCC, or with another antibody, or with a fluorophore, or with any other molecules or ligand such as nanoparticles, metals or radioelements, for imaging, and/or for therapeutic and/or for theranostic use.
number: 14
text: A composition comprising a therapeutically effective amount of a compound according to anyone of the preceding claims.
number: 15
text: A host cell that produces an isolated antibody according to anyone of claims 6 to 13.
number: 16
text: An isolated nucleic acid sequence encoding an antibody as defined in anyone of claims 6 to 13, comprising a nucleic acid encoding at least one sequence of the group consisting of :
number: 17
text: An expression vector comprising a nucleic acid as defined in claim 16.
number: 18
text: A method of producing an antibody as defined in anyone of claims 6 to 11, comprising culturing the host cell as defined in claim 13 under conditions that result in production of said antibody, and isolating said antibody from the host cell or culture medium of the host cell.
number: 19
text: A compound as defined in anyone of claims 1 to 13, for its use as a drug.
number: 20
text: A compound as defined in anyone of claims 1 to 13, for its use in treating a condition or a disorder in which the STIM1 protein localized to the plasma membrane of the cells is overexpressed.
number: 21
text: A compound for its use according to claim 20, wherein the condition or disorder is selected from a pathology with an increase in specific cells of mSTIM1 expression such as Systemic Lupus Erythematous or Chronic Lymphocytic Leukemia therefore any autoimmune disease, immunological, cancer, cardiovascular, muscular, neurological, hematological, inflammatatory, respiratory, infectious endocrine, cutaneous, gastrointestinal, metabolic, allergic diseases and in transplantation with an increase in specific expression cells of mSTIM1.
number: 22
text: An isolated protein fragment consisting of all or part of the region between amino acid residues 58 and 201 of the STIM1 amino acid sequence SEQ ID NO: 1.
number: 23
text: An isolated protein fragment according to claim 22, consisting of the region between amino acid residues 128 and 168 of the STIM1 amino acid sequence SEQ ID NO: 1.
number: 24
text: Use of an isolated protein fragment as defined in claim 22 or 23, for producing a compound that specifically binds to the region between amino acid residues 58 and 201 of the STIM1 amino acid sequence SEQ ID NO: 1.
number: 25
text: Use of the protein fragment as defined in claim 24, for developing compounds that specifically binds to the region between amino acid residues 58 and 201 of the STIM1 amino acid sequence SEQ ID NO: 1 and modulates STIM1 activity.
Office action: search_report, dated 2020-09-30
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: EP2982982A1
ref_type: patent
severity: background
ref_id: EP3062105A1
ref_type: patent
severity: background
ref_id: - MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851 - 55
ref_type: npl
severity: background
ref_id: - HARLOW ET AL.: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBORLABORATORY PRESS
ref_type: npl
severity: background
ref_id: - HAMMERLING ET AL.: "Monoclonal Antibodies and T-Cell Hybridomas", 1981, ELSEVIER, pages: 563 - 681
ref_type: npl
severity: background
ref_id: - JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
ref_type: npl
severity: background
ref_id: - RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ref_type: npl
severity: background
ref_id: - PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
ref_type: npl
severity: background
ref_id: - HARLOW ET AL.: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: WO2004078995A2
ref_type: patent
severity: background
ref_id: WO2016020274A1
ref_type: patent
severity: background
ref_id: WO2016135273A1
ref_type: patent
severity: background
ref_id: WO2009124973A1
ref_type: patent
severity: background
ref_id: WO2009115609A1
ref_type: patent
severity: background
ref_id: - JARDIN I ET AL: "Store-operated Ca^2^+ entry is sensitive to the extracellular Ca2+ concentration through plasma membrane STIM1", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1793, no. 10, 1 October 2009 (2009-10-01), pages 1614 - 1622, XP026585930, ISSN: 0167-4889, [retrieved on 20090723], DOI: 10.1016/J.BBAMCR.2009.07.003
ref_type: npl
severity: background
ref_id: - ANONYMOUS: "Human/Mouse/Rat STIM1 Antibody, Clone # 705111, Catalog Number: MAB6976", 2 July 2018 (2018-07-02), XP055647664, Retrieved from the Internet <URL:https://resources.rndsystems.com/pdfs/datasheets/mab6976.pdf> [retrieved on 20191129]
ref_type: npl
severity: background
ref_id: - MYKOLA MAMENKO ET AL: "Defective Store-Operated Calcium Entry Causes Partial Nephrogenic Diabetes Insipidus", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY., vol. 27, no. 7, 16 November 2015 (2015-11-16), US, pages 2035 - 2048, XP055647665, ISSN: 1046-6673, DOI: 10.1681/ASN.2014121200
ref_type: npl
severity: background
ref_id: WO2004078995
ref_type: patent
severity: novelty_destroying
ref_id: WO2009115609
ref_type: patent
severity: background
ref_id: WO2009124973
ref_type: patent
severity: background
ref_id: WO2016020274
ref_type: patent
severity: novelty_destroying
ref_id: WO2016135273
ref_type: patent
severity: novelty_destroying
ref_id: - JARDIN I ET AL, "Store-operated Ca^2^+ entry is sensitive to the extracellular Ca2+ concentration through plasma membrane STIM1", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1793, no. 10, doi:10.1016/J.BBAMCR.2009.07.003, ISSN 0167-4889, (20091001), pages 1614 - 1622, (20090723), XP026585930 [X] 1,3,4,6,11,14,15,18-21 * page  1615, column  l, paragraph  1 * * page  1619, column  r, paragraph  2 * * page  1617, column  l, paragraph  4  - column  r, paragraph  1 * [I] 2,5,7-10,12,13,16,17,22-25
ref_type: npl
severity: novelty_destroying
ref_id: - Anonymous, "Human/Mouse/Rat STIM1 Antibody, Clone # 705111, Catalog Number: MAB6976", (20180702), URL: https://resources.rndsystems.com/pdfs/datasheets/mab6976.pdf, (20191129), XP055647664 [X] 1-4,6,11,14,15,18-21 * the whole document * [I] 5,7-10,12,13,16,17,22-25
ref_type: npl
severity: novelty_destroying
ref_id: - MYKOLA MAMENKO ET AL, "Defective Store-Operated Calcium Entry Causes Partial Nephrogenic Diabetes Insipidus", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY., US, (20151116), vol. 27, no. 7, doi:10.1681/ASN.2014121200, ISSN 1046-6673, pages 2035 - 2048, XP055647665 [X] 1,3,4,6,11,14,15,18-21 * page  2037, column  l, paragraph  1 * * Legend of Figure 2 * * page  2046, column  r, paragraph  1 * [I] 2,5,7-10,12,13,16,17,22-25
ref_type: npl
severity: novelty_destroying
Final disposition: pending (2020-09-30)